Form 4: Xeris Biopharma Director Sells Over 100K Shares

Xeris Biopharma Director John Johnson sold 107,500 shares of common stock for approximately $7.32 per share.

Summary

• Director John Johnson of Xeris Biopharma Holdings, Inc. sold 107,500 shares of common stock.
• The transaction occurred on August 13, 2025.
• The shares were sold at a weighted average price of $7.3159 per share, with prices ranging from $7.250 to $7.420.
• Following the sale, John Johnson beneficially owns 833,483 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• 墾,
• positives": [ "The sale was conducted pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled transaction and not necessarily a reaction to new, adverse material information.

Sentiment

Score: 4

Explanation: A director sold a significant number of shares, which can be perceived negatively. However, the sale was conducted under a pre-arranged 10b5-1 plan, suggesting it was not based on new, adverse material information, thus mitigating the negative sentiment.

Negatives

• A director sold a significant number of shares (107,500 shares), reducing their direct beneficial ownership in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director John Johnson sold 107,500 shares of Xeris Biopharma Holdings, Inc. common stock.

Stakeholder Impact

• Shareholders: Potential negative sentiment due to insider selling, although mitigated by the pre-arranged 10b5-1 plan.

Key Dates

Recommendation

The sale by a director, while notable, was conducted under a pre-arranged 10b5-1 plan, which suggests it was not driven by new, adverse material information. Without additional context on the company's performance or other market factors, this single transaction does not provide a strong signal for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate.

Keywords

Xeris Biopharma, XERS, insider trading, Form 4, stock sale, director, common stock, beneficial ownership